tumoral angiogenesis
Tumor angiogenesis is mediated by a balance of activators and inhibitors.
VEGF
Among them, VEGF is a key activator via the tyrosine kinase receptors VEGFR1, VEGFR2, and VEGFR3 (VGFRs).
Neuropilin-1 (NRP1) (MIM.602069) and neuropilin-2 (NRP2) (MIM.602070) are other transmembrane VEGF receptors (see NRPs). They were initially identified on neuronal cells as receptors for class 3 semaphorins (SEMA). The NP1 and NP2 receptors (NP2 shares 47% homology with NP1) are VEGF cor-eceptors that specifically enhance the interaction of VEGF with VEGFR2.
The function of NP1 and NP2 in carcinomas is not well known; however, NP1 overexpression is a marker of aggressiveness in prostate cancer in vivo and increases angiogenesis in colon and pancreatic cancer in vitro and [16].
Videos
tumoral angiogenesis (1?12??)
References
Ruegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med. 2003 Dec;3(8):673-91. PMID: 14682490
Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005 Feb;15(1):102-11. PMID: 15661540
Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003 Jun;3(6):422-33. PMID: 12778132
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 Jun;3(6):401-10. PMID: 12778130
Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002 Feb;2(2):83-90. PMID: 12635171
Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor?s gateway to progression along the angiogenic pathway. Trends Cell Biol. 2001 Nov;11(11):S32-6. PMID: 11684440
de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med. 2001 Sep;7(9):401-7. PMID: 11530335